{Reference Type}: Journal Article
{Title}: Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor.
{Author}: Brösecke F;Pfau A;Ermer T;Dein Terra Mota Ribeiro AB;Rubenbauer L;Rao VS;Burlein S;Genser B;Reichel M;Aronson PS;Coca S;Knauf F;
{Journal}: Sci Rep
{Volume}: 14
{Issue}: 1
{Year}: 2024 05 17
{Factor}: 4.996
{DOI}: 10.1038/s41598-024-61808-7
{Abstract}: Oxalate, a uremic toxin that accumulates in dialysis patients, is associated with cardiovascular disease. As oxalate crystals can activate immune cells, we tested the hypothesis that plasma oxalate would be associated with cytokine concentrations and cardiovascular outcomes in dialysis patients. In a cohort of 104 US patients with kidney failure requiring dialysis (cohort 1), we measured 21 inflammatory markers. As IL-16 was the only cytokine to correlate with oxalate, we focused further investigations on IL-16. We searched for associations between concentrations of IL-16 and mortality and cardiovascular events in the 4D cohort (1255 patients, cohort 2) and assessed further associations of IL-16 with other uremic toxins in this cohort. IL-16 levels were positively correlated with pOx concentrations (ρ = 0.39 in cohort 1, r = 0.35 in cohort 2) and were elevated in dialysis patients when compared to healthy individuals. No significant association could be found between IL-16 levels and cardiovascular events or mortality in the 4D cohort. We conclude that the cytokine IL-16 correlates with plasma oxalate concentrations and is substantially increased in patients with kidney failure on dialysis. However, no association could be detected between IL-16 concentrations and cardiovascular disease in the 4D cohort.